MedTrace Logo

Photoprotection Efficacy of a Sunscreen Under Visible Light Exposure by Using Two Different Simulators

NCT06796140 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-01-30

No results posted yet for this study

Summary

To assess the ability of a protected agent to prevent the pigmentation under visible light exposures (VL) using two different simulators in healthy volunteers

Conditions

  • Visible Light Exposures on Healthy Back Skin

Interventions

OTHER

Visible Light Exposure - Treated zone - Left hemi-back

The treated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

OTHER

Visible Light Exposure - Treated zone - Right hemi-back

The treated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

OTHER

Visible Light Exposure - Untreated zone - Left hemi-back

The untreated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.

OTHER

Visible Light Exposure - Untreated zone - Right hemi-back

The untreated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.

Sponsors & Collaborators

  • Cosmetique Active International

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2021-04-09
Completion
2021-04-09

Countries

  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06796140 on ClinicalTrials.gov